Kizoo Announces Support for N-LIfT Cancer Immunotherapy

STEVE HILL | August 12, 2019 | 3 views

Kizoo, part of the Forever Healthy Foundation, has announced today that it will be supporting biotech company LIfT Biosciences, a company that focuses on creating a new generation of cancer therapies that use our own immune systems.

Spotlight

Laureate Biopharmaceutical Services

Gallus BioPharmaceuticals, LLC has been acquired by DPx Holdings B.V., privately owned by JLL Partners and Royal DSM and the parent company of Patheon. Patheon’s biologic drug substance business, a unit of DPx Holdings, now spans four global facilities in Europe, Australia and North America and includes more than 550 employees.

OTHER ARTICLES

Advancement in Genomics Accelerating its Penetration into Precision Health

Article | April 17, 2020

Genomics is an interdisciplinary field of biology emphasizing the structure, editing, evolution, function, and mapping of genomes. It is creating deeper inroads across the precision health domain with the increasing introduction of advanced technologies such as quantum simulation, next-generation sequencing (NGS), and precise genome manipulation. As precision health focuses on providing the proper intervention to the right patient at the right time, genomics increasingly finds applications in human and pathogen genome sequencing in clinical and research spaces. Rising Hereditary Diseases Burden Paving the Way for Genomics in Precision Health In the last few years, a significant surge in the prevalence of diseases and ailments such as diabetes, obesity, baldness, and others has been witnessed across the globe. A history of family members with chronic diseases, such as cancer, diabetes, high blood pressure, hearing issues, and heart disease, can sometimes continue into the next generation. Hence, the study of genes is extensively being conducted for predicting health risks and early treatment of these diseases. It also finds use in CRISPR-based diagnostics and the preparation of precision medication for the individual. In addition, ongoing advancements in genomics are making it possible to identify different genetic traits that persuade people to more widespread diseases and health problems. The Emergence of Genomics Improves Disease Understanding Genomics refers to the study of the complete genetic makeup of a cell or organism. Increasing scientific research in the area substantially contributes to increasing knowledge about the human genome and assists in improving the ability to understand disease etiology, risk, diagnosis, treatment, and prevention. On account of these improvements, innovative genomic technologies and tools are being developed to enable better precision health not only for the individual but for various regional populations as well. The Way Forward With growing preference for personalized medicine and an increasing need for more accurate pathogen detection and diagnostics, genomics is gaining huge popularity across the precision health domain. Also, increasing research activities for developing novel high-precision therapeutics and rising importance of gene study in the prevention, diagnosis, and management of infectious and genetic diseases will further pave the way for genomics in the forthcoming years.

Read More

Top 10 biotech IPOs in 2019

Article | September 13, 2019

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | April 19, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | February 12, 2020

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Spotlight

Laureate Biopharmaceutical Services

Gallus BioPharmaceuticals, LLC has been acquired by DPx Holdings B.V., privately owned by JLL Partners and Royal DSM and the parent company of Patheon. Patheon’s biologic drug substance business, a unit of DPx Holdings, now spans four global facilities in Europe, Australia and North America and includes more than 550 employees.

Related News

Is Immunotherapy Working? Just Ask AI

Technology Networks | November 25, 2019

Scientists from the Case Western Reserve University digital imaging lab, already pioneering the use of Artificial Intelligence (AI) to predict whether chemotherapy will be successful, can now determine which lung-cancer patients will benefit from expensive immunotherapy. And, once again, they’re doing it by teaching a computer to find previously unseen changes in patterns in CT scans taken when the lung cancer is first diagnosed compared to scans taken after the first 2-3 cycles of immunotherapy treatment. And, as with previous work, those changes have been discovered both inside—and outside—the tumor, a signature of the lab’s recent research. “This is no flash in the pan—this research really seems to be reflecting something about the very biology of the disease, about which is the more aggressive phenotype, and that’s information oncologists do not currently have,” said Anant Madabhushi, whose Center for Computational Imaging and Personalized Diagnostics (CCIPD) researches the detection, diagnosis and characterization of various cancers and other diseases by meshing medical imaging, machine learning and AI. Currently, only about 20% of all cancer patients will actually benefit from immunotherapy, a treatment that differs from chemotherapy in that it uses drugs to help your immune system fight cancer, while chemotherapy uses drugs to directly kill cancer cells, according to the National Cancer Institute.

Read More

Personalized Immunotherapy Refined by Mass Spec-Machine Learning Pairing

Technology Networks | October 16, 2019

Ludwig Cancer Research scientists have developed a new and more accurate method to identify the molecular signs of cancer likely to be presented to helper T cells, which stimulate and orchestrate the immune response to tumors and infectious agents. The study, led by David Gfeller and Michal Bassani-Sternberg of the Lausanne Branch of the Ludwig Institute for Cancer Research, is reported in the current issue of Nature Biotechnology. The new method combines two powerful new technologies. One is a mass spectrometry technology developed by Bassani-Sternberg’s lab to rapidly and inexpensively obtain the amino acid sequences of thousands of peptide antigens—or protein fragments—bound to a molecular complex known as HLA that is expressed on the surface of cells. The other is a novel computational tool developed in Gfeller’s lab that is based on machine learning, the computational approach that powers face-recognition software, among other things. “This method advances our effort to find good targets for cancer immunotherapy,” says Bassani-Sternberg. “But it is not only important for vaccines and other immunotherapies. It is also a tool we will be using for basic science, to better understand the interaction of cancers with the immune system.”

Read More

Zacks Podcast Highlights: Immunotherapy Stocks 101: What Biotech Investors Need to Know Now

Amgen | December 28, 2016

In this edition of the Dutram Report , Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments. Brad specializes in the world of immunotherapy, a technique that is revolutionizing the cancer treatment market by harnessing the power of someone's immune system to fight disease. We get to the bottom of this emerging technology in the podcast so that investors can better understand why this market may deserve a closer look in 2017.

Read More

Is Immunotherapy Working? Just Ask AI

Technology Networks | November 25, 2019

Scientists from the Case Western Reserve University digital imaging lab, already pioneering the use of Artificial Intelligence (AI) to predict whether chemotherapy will be successful, can now determine which lung-cancer patients will benefit from expensive immunotherapy. And, once again, they’re doing it by teaching a computer to find previously unseen changes in patterns in CT scans taken when the lung cancer is first diagnosed compared to scans taken after the first 2-3 cycles of immunotherapy treatment. And, as with previous work, those changes have been discovered both inside—and outside—the tumor, a signature of the lab’s recent research. “This is no flash in the pan—this research really seems to be reflecting something about the very biology of the disease, about which is the more aggressive phenotype, and that’s information oncologists do not currently have,” said Anant Madabhushi, whose Center for Computational Imaging and Personalized Diagnostics (CCIPD) researches the detection, diagnosis and characterization of various cancers and other diseases by meshing medical imaging, machine learning and AI. Currently, only about 20% of all cancer patients will actually benefit from immunotherapy, a treatment that differs from chemotherapy in that it uses drugs to help your immune system fight cancer, while chemotherapy uses drugs to directly kill cancer cells, according to the National Cancer Institute.

Read More

Personalized Immunotherapy Refined by Mass Spec-Machine Learning Pairing

Technology Networks | October 16, 2019

Ludwig Cancer Research scientists have developed a new and more accurate method to identify the molecular signs of cancer likely to be presented to helper T cells, which stimulate and orchestrate the immune response to tumors and infectious agents. The study, led by David Gfeller and Michal Bassani-Sternberg of the Lausanne Branch of the Ludwig Institute for Cancer Research, is reported in the current issue of Nature Biotechnology. The new method combines two powerful new technologies. One is a mass spectrometry technology developed by Bassani-Sternberg’s lab to rapidly and inexpensively obtain the amino acid sequences of thousands of peptide antigens—or protein fragments—bound to a molecular complex known as HLA that is expressed on the surface of cells. The other is a novel computational tool developed in Gfeller’s lab that is based on machine learning, the computational approach that powers face-recognition software, among other things. “This method advances our effort to find good targets for cancer immunotherapy,” says Bassani-Sternberg. “But it is not only important for vaccines and other immunotherapies. It is also a tool we will be using for basic science, to better understand the interaction of cancers with the immune system.”

Read More

Zacks Podcast Highlights: Immunotherapy Stocks 101: What Biotech Investors Need to Know Now

Amgen | December 28, 2016

In this edition of the Dutram Report , Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments. Brad specializes in the world of immunotherapy, a technique that is revolutionizing the cancer treatment market by harnessing the power of someone's immune system to fight disease. We get to the bottom of this emerging technology in the podcast so that investors can better understand why this market may deserve a closer look in 2017.

Read More

Events